Market Summary
USD81.91+2.43
Delayed3.06%
EW Alerts
EW Stock Price
EW RSI Chart
EW Valuation
EW Price/Sales (Trailing)
EW Profitability
EW Fundamentals
EW Revenue
EW Earnings
Price Action
52 Week Range
67.13131.10
(Low)(High)
Last 7 days
2.9%
Last 30 days
2.4%
Last 90 days
8.1%
Trailing 12 Months
-25.1%
EW Financial Health
EW Investor Care
Peers (Alternatives to Edwards Lifesciences)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MDT | 105.5B | 30.8B | -7.09% | -24.59% | 25.94 | 3.43 | -3.19% | -17.38% |
SYK | 104.1B | 18.4B | 2.26% | 8.00% | 44.16 | 5.64 | 7.84% | 18.25% |
ISRG | 84.2B | 6.2B | -4.47% | -13.27% | 63.66 | 13.53 | 8.97% | -22.43% |
BDX | 67.4B | 19.0B | -5.16% | -6.78% | 41.86 | 3.55 | -0.43% | -8.78% |
EW | 49.8B | 5.4B | 2.41% | -25.12% | 32.74 | 9.26 | 2.86% | 1.25% |
| MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 9.34% | 31.15% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.2B | 847.1M | -3.64% | 34.52% | -5.1K | 12.05 | 13.32% | -137.89% |
GMED | 5.2B | 1.0B | -11.64% | -20.31% | 30.19 | 5.09 | 6.76% | 24.45% |
IRTC | 3.5B | 410.9M | 4.51% | -3.13% | -29.82 | 8.43 | 27.29% | -14.60% |
TNDM | 2.7B | 801.2M | 1.13% | -58.87% | -28.25 | 3.34 | 14.00% | -707.69% |
| SMALL-CAP | ||||||||
SILK | 1.7B | 138.6M | -15.68% | 29.18% | -30.43 | 12.07 | 36.62% | -10.44% |
AVNS | 1.3B | 820.0M | -8.35% | -12.22% | 25.89 | 1.59 | 10.13% | 701.59% |
BLFS | 853.3M | 154.8M | -6.04% | 0.61% | -8.2 | 5.51 | 60.29% | -2309.58% |
CSII | 828.4M | 239.8M | 0.30% | 1.49% | -21.88 | 3.45 | -4.74% | -31.15% |
Financials for Edwards Lifesciences
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 0.3% | 5,382 | 5,364 | 5,355 | 5,357 | 5,233 |
| Gross Profit | 1.7% | 4,302 | 4,232 | 4,165 | 4,102 | 3,984 |
| S&GA Expenses | -0.8% | 1,568 | 1,581 | 1,568 | 1,533 | 1,494 |
| R&D Expenses | -0.1% | 945 | 946 | 950 | 925 | 903 |
| EBITDA | 4.1% | 1,926 | 1,850 | 1,824 | 1,905 | - |
| EBITDA Margin | 3.8% | 0.36* | 0.34* | 0.34* | 0.36* | - |
| Earnings Before Taxes | 4.9% | 1,767 | 1,684 | 1,668 | 1,749 | 1,702 |
| EBT Margin | 4.6% | 0.33* | 0.31* | 0.31* | 0.33* | - |
| Interest Expenses | -32.2% | 19.00 | 28.00 | 21.00 | 19.00 | 18.00 |
| Net Income | 4.3% | 1,522 | 1,459 | 1,455 | 1,539 | 1,503 |
| Net Income Margin | 4.0% | 0.28* | 0.27* | 0.27* | 0.29* | - |
| Free Cahsflow | -6.7% | 974 | 1,044 | 1,265 | 1,432 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -4.0% | 8,293 | 8,638 | 8,425 | 8,420 | 8,503 |
| Current Assets | -11.9% | 3,096 | 3,514 | 3,263 | 3,241 | 3,181 |
| Cash Equivalents | -38.4% | 769 | 1,248 | 1,198 | 1,031 | 863 |
| Inventory | 15.5% | 876 | 758 | 740 | 731 | 727 |
| Net PPE | 4.2% | 1,633 | 1,566 | 1,560 | 1,552 | 1,547 |
| Goodwill | 0.5% | 1,164 | 1,159 | 1,164 | 1,166 | 1,168 |
| Liabilities | 2.7% | 2,486 | 2,420 | 2,482 | 2,575 | 2,667 |
| Current Liabilities | 11.4% | 1,022 | 918 | 969 | 950 | 1,032 |
| LT Debt, Non Current | 0.0% | 596 | 596 | 596 | 596 | 596 |
| Shareholder's Equity | -6.6% | 5,807 | 6,218 | 5,944 | 5,845 | 5,836 |
| Retained Earnings | 5.5% | 7,590 | 7,192 | 6,848 | 6,442 | 6,068 |
| Additional Paid-In Capital | 2.9% | 1,969 | 1,915 | 1,853 | 1,769 | 1,700 |
| Accumulated Depreciation | 14.6% | 750 | 655 | - | - | - |
| Shares Outstanding | -1.8% | 608 | 619 | 620 | 621 | 624 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -6.9% | 1,218 | 1,309 | 1,531 | 1,725 | 1,732 |
| Share Based Compensation | 3.0% | 127 | 123 | 119 | 114 | 109 |
| Cashflow From Investing | 131.2% | 252 | -808 | -984 | -1,443 | -1,722 |
| Cashflow From Financing | -96.1% | -1,584 | -808 | -699 | -450 | -356 |
| Buy Backs | 80.4% | 1,727 | 958 | 859 | 616 | 513 |
Risks for EW
What is the probability of a big loss on EW?
39.6%
Probability that Edwards Lifesciences stock will be more than 20% underwater in next one year
31.9%
Probability that Edwards Lifesciences stock will be more than 30% underwater in next one year.
8.1%
Probability that Edwards Lifesciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does EW drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Edwards Lifesciences was unfortunately bought at previous high price.
Drawdowns
Returns for EW
Cumulative Returns on EW
33.1%
10-Year Cumulative Returns
35.4%
7-Year Cumulative Returns
38.1%
5-Year Cumulative Returns
56.8%
3-Year Cumulative Returns
What are the long-term rolling returns for EW?
FIve years rolling returns for Edwards Lifesciences.
Annualized Returns
Which funds bought or sold EW recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -12.31 | -678,508 | 2,579,490 | 0.07% |
2023-03-13 | Claro Advisors LLC | reduced | -15.7 | -206,942 | 405,058 | 0.13% |
2023-03-10 | MATHER GROUP, LLC. | added | 122 | 240,355 | 477,355 | 0.01% |
2023-03-10 | MATHER GROUP, LLC. | sold off | -100 | -402,000 | - | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -61.4 | -33,648,700 | 18,003,300 | 0.02% |
2023-03-10 | BAILLIE GIFFORD & CO | added | 0.77 | -3,216,020 | 32,492,000 | 0.03% |
2023-03-08 | Capital Asset Advisory Services LLC | new | - | 303,887 | 303,887 | 0.02% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -80.43 | -22,180,000 | 4,760,000 | 0.02% |
2023-03-03 | TIAA, FSB | reduced | -88.56 | -7,335,270 | 844,734 | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 72,412,600 | 72,412,600 | 0.90% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
EW Alerts
Edwards Lifesciences News
Schedule 13G FIlings of Edwards Lifesciences
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 8.34% | 51,559,391 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 8.6% | 53,060,508 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 7.86% | 49,076,649 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 9.1% | 57,040,983 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 7.76% | 48,347,685 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 9.4% | 58,596,560 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 7.79% | 16,261,702 | SC 13G/A | |
| Feb 05, 2020 | blackrock inc. | 8.7% | 18,200,799 | SC 13G/A |
EW Fair Value
Edwards Lifesciences fair value in different scenarios
The table shows the Fair Value estimates for Edwards Lifesciences for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 34.98 -57.29% | 45.99 -43.85% | 62.21 -24.05% | 80.13 -2.17% | 94.13 14.92% |
| Current Inflation | 32.13 -60.77% | 41.56 -49.26% | 55.09 -32.74% | 69.98 -14.56% | 81.59 -0.39% |
| Very High Inflation | 28.63 -65.05% | 36.22 -55.78% | 46.71 -42.97% | 58.26 -28.87% | 67.21 -17.95% |
Historical Edwards Lifesciences Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Edwards Lifesciences
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 15, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | PRE 14A | PRE 14A | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Feb 21, 2023 | 8-K | Current Report | |
| Feb 21, 2023 | 4 | Insider Trading | |
| Feb 17, 2023 | 4 | Insider Trading | |
| Feb 17, 2023 | 4 | Insider Trading | |
| Feb 16, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for EW
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-15 | Chopra Daveen | acquired | 200,802 | 45.2767 | 4,435 | cvp, tmtt |
2023-03-15 | Chopra Daveen | sold | -343,563 | 77.4662 | -4,435 | cvp, tmtt |
2023-03-14 | MUSSALLEM MICHAEL A | acquired | 1,033,900 | 35.1967 | 29,375 | chairman & ceo |
2023-03-14 | MUSSALLEM MICHAEL A | gifted | - | - | 9,500 | chairman & ceo |
2023-03-14 | MUSSALLEM MICHAEL A | sold | -1,542,510 | 77.6107 | -19,875 | chairman & ceo |
2023-03-14 | MUSSALLEM MICHAEL A | gifted | - | - | -9,500 | chairman & ceo |
2023-03-08 | Lemercier Jean-Luc M | acquired | 233,706 | 35.1967 | 6,640 | cvp, emeacla and japac |
2023-03-08 | Lemercier Jean-Luc M | sold | -510,996 | 76.9573 | -6,640 | cvp, emeacla and japac |
2023-03-08 | BOBO DONALD E JR | sold | -517,558 | 76.9603 | -6,725 | cvp,strategy/corp development |
2023-03-08 | BOBO DONALD E JR | acquired | 236,698 | 35.1967 | 6,725 | cvp,strategy/corp development |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW Income Statement
2022-09-30CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
| Income Statement [Abstract] | ||||
| Net sales | $ 1,319.0 | $ 1,310.2 | $ 4,034.1 | $ 3,902.8 |
| Cost of sales | 253.8 | 311.7 | 822.5 | 939.4 |
| Gross profit | 1,065.2 | 998.5 | 3,211.6 | 2,963.4 |
| Selling, general, and administrative expenses | 377.3 | 364.4 | 1,156.6 | 1,069.7 |
| Research and development expenses | 233.6 | 238.0 | 713.0 | 670.3 |
| Intellectual property litigation (income) expenses, net | (2.4) | 4.7 | 10.8 | 13.5 |
| Change in fair value of contingent consideration liabilities, net (Note 7) | (12.5) | 1.1 | (36.3) | (106.0) |
| Special charge (Note 3) | 66.8 | 0.0 | 66.8 | 0.0 |
| Operating income | 402.4 | 390.3 | 1,300.7 | 1,315.9 |
| Interest (income) expense, net | (6.9) | 0.8 | (8.4) | 1.5 |
| Other expense (income), net | 2.0 | (1.4) | 1.0 | (11.3) |
| Income before provision for income taxes | 407.3 | 390.9 | 1,308.1 | 1,325.7 |
| Provision for income taxes | 63.8 | 50.8 | 184.6 | 157.9 |
| Net income | $ 343.5 | $ 340.1 | $ 1,123.5 | $ 1,167.8 |
| Earnings per share: | ||||
| Basic (in dollars per share) | $ 0.55 | $ 0.55 | $ 1.81 | $ 1.87 |
| Diluted (in dollars per share) | $ 0.55 | $ 0.54 | $ 1.79 | $ 1.85 |
| Weighted-average number of common shares outstanding: | ||||
| Basic (in shares) | 619.8 | 623.6 | 621.0 | 623.0 |
| Diluted (in shares) | 624.5 | 631.7 | 626.9 | 631.0 |
EW Balance Sheet
2022-09-30CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 1,247.8 | $ 862.8 |
| Short-term investments (Note 4) | 490.9 | 604.0 |
| Accounts receivable, net of allowances of $7.5 and $9.3, respectively | 618.1 | 582.2 |
| Other receivables | 43.3 | 82.7 |
| Inventories (Note 2) | 757.8 | 726.7 |
| Prepaid expenses | 88.4 | 85.2 |
| Other current assets | 267.6 | 237.1 |
| Total current assets | 3,513.9 | 3,180.7 |
| Long-term investments (Note 4) | 1,381.0 | 1,834.2 |
| Property, plant, and equipment, net | 1,566.4 | 1,546.6 |
| Operating lease right-of-use assets | 87.7 | 92.1 |
| Goodwill | 1,158.7 | 1,167.9 |
| Other intangible assets, net (Note 3) | 266.5 | 323.6 |
| Deferred income taxes | 347.5 | 246.7 |
| Other assets (Note 5) | 316.5 | 110.8 |
| Total assets | 8,638.2 | 8,502.6 |
| Current liabilities | ||
| Accounts payable | 154.9 | 204.5 |
| Accrued and other liabilities (Note 2) | 739.5 | 802.3 |
| Operating lease liabilities | 23.5 | 25.5 |
| Total current liabilities | 917.9 | 1,032.3 |
| Long-term debt | 596.2 | 595.7 |
| Contingent consideration liabilities (Note 7) | 25.7 | 62.0 |
| Taxes payable | 142.9 | 190.0 |
| Operating lease liabilities | 67.1 | 69.1 |
| Uncertain tax positions | 295.6 | 259.0 |
| Litigation settlement accrual (Note 2) | 153.9 | 191.3 |
| Other liabilities | 221.1 | 267.3 |
| Total liabilities | 2,420.4 | 2,666.7 |
| Commitments and contingencies (Note 11) | ||
| Stockholders' equity | ||
| Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding | 0.0 | 0.0 |
| Common stock, $1.00 par value, 1,050.0 shares authorized, 645.7 and 642.0 shares issued, and 619.4 and 624.1 shares outstanding, respectively | 645.7 | 642.0 |
| Additional paid-in capital | 1,914.5 | 1,700.4 |
| Retained earnings | 7,191.6 | 6,068.1 |
| Accumulated other comprehensive loss (Note 12) | (256.0) | (157.7) |
| Treasury stock, at cost, 26.3 and 17.9 shares, respectively | (3,278.0) | (2,416.9) |
| Total stockholders' equity | 6,217.8 | 5,835.9 |
| Total liabilities and stockholders' equity | $ 8,638.2 | $ 8,502.6 |